<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="treatment of Covid-19. Methods CP treatment was applied to 26" exact="Covid-19" post="patients in intensive care unit who had quantitative reverse"/>
 <result pre="Sars-Cov-2 infection. The collected CP (200cc) were applied to severe" exact="Covid-19" post="patients. Laboratory values of patients just before CP and"/>
 <result pre="before specific vaccines and treatments are developed. In early stage" exact="Covid-19" post="patients who do not need mechanical ventilation, CP treatment"/>
 <result pre="be a curative treatment option. Keywords Convalescent plasma Sars-Cov-2 infection" exact="Covid-19" post="Coronavirus Immun plasma 1 Introduction A pneumonia associated with"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China [1]. The" exact="SARS-CoV-2 infection" post="spread rapidly all over the world. As of June"/>
 <result pre="423.349 deaths [2]. There are currently no proven treatment for" exact="Coronavirus disease 2019" post="(Covid-19). There is no effective antiviral drug in the"/>
 <result pre="There is no effective antiviral drug in the treatment of" exact="Covid-19" post="disease. It is an urgent need to seek an"/>
 <result pre="the administration of antibodies collected from recently infected and recovered" exact="Covid-19" post="patients to Covid-19 patients for therapeutic purposes. CP was"/>
 <result pre="antibodies collected from recently infected and recovered Covid-19 patients to" exact="Covid-19" post="patients for therapeutic purposes. CP was used during the"/>
 <result pre="[4]. However, the benefit of CP treatment to mortality in" exact="Ebola" post="virus disease has not been showed [5]. Recently, CP"/>
 <result pre="as a effective and reliable treatment option in SARS-CoV-1 and" exact="Middle East respiratory syndrome" post="(MERS) epidemics [6]. Therefore, it suggested that the use"/>
 <result pre="and lopinavirâ€‰+â€‰ritonavirâ€‰+â€‰interferon-beta. There is widespread interest to CP from recovered" exact="Covid-19" post="patients as treatment. The United States Food and Drug"/>
 <result pre="time in the world after China in the treatment of" exact="Covid-19" post="disease. The purpose of this study was to share"/>
 <result pre="share our clinical experience with CP transfusion administered to severe" exact="Covid-19" post="patients. 2 Materials and methods 2.1 Study design CP"/>
 <result pre="methods 2.1 Study design CP treatment was applied to 26" exact="Covid-19" post="patients in intensive care unit who had quantitative reverse"/>
 <result pre="starting the procedure, PCR was confirmed to be negative for" exact="Covid-19" post="in both the swab and serum of the donor."/>
 <result pre="sterile combining set. The collected CPs were applied to severe" exact="Covid-19" post="patients. Laboratory values of patients just before CP and"/>
 <result pre="2020 under the number 2020/77. 2.2 Study population PCR positive" exact="Covid-19" post="patients who received CP treatment were included in the"/>
 <result pre="the study. Patients with no PCR positivity and strongly suspected" exact="Covid-19" post="disease were excluded from the study. In addition to"/>
 <result pre="and dead patients. pâ€‰ 3 Results A total of twenty-six" exact="Covid-19" post="patients (8 females and 18 males) with a mean"/>
 <result pre="who did not need mechanical ventilation died. Of the 26" exact="Covid-19" post="patients included in the study, 20 were alive and"/>
 <result pre="0,018 4 Discussion There is no specific therapeutic agent for" exact="Covid-19" post="disease. Treatment of the disease and prevention of its"/>
 <result pre="of the treatment options used in the current treatment of" exact="Covid-19" post="are hydroxychloroquine, lopinavir / ritonavir, azithromycin, favipiravir and Interleukin-6"/>
 <result pre="the use of passive antibody transfer is considered for treating" exact="Covid-19" post="patients. The FDA has approved the use of experimental"/>
 <result pre="use of experimental CP therapy in clinical trials and critical" exact="Covid-19" post="patients without other treatment options, and has published a"/>
 <result pre="Ahn et al. applied 200â€‰mL CP therapy to two serious" exact="Covid-19" post="patients aged 67 and 71, whose anti-SARS-CoV-2 IgG antibody"/>
 <result pre="1: 640) to the treatment of 10 critical patients with" exact="Covid-19" post="(age range 34â€&quot;78) after an average of 16.5 days"/>
 <result pre="a meta-analysis to investigate the effect of CP therapy on" exact="Covid-19" post="disease [7]. They identified the reliability of CP treatment."/>
 <result pre="al., added CP in addition to standard therapy in 103" exact="Covid-19" post="patients. The trial was conducted in open, multicentric randomized"/>
 <result pre="two groups [17]. Zhang et al. reported that 4 critical" exact="Covid-19" post="patients who received supportive therapy were cured with CP"/>
 <result pre="be confirmed by randomized studies [18]. In our trial, twenty-six" exact="Covid-19" post="patients had no severe adverse reactions after CP transfusion."/>
 <result pre="CP looks to be effective for a better follow of" exact="Covid-19" post="when administered in severe and critically ill patients and"/>
 <result pre="care unit hospitalization. We observed that all patients with early-stage" exact="Covid-19" post="who did not need mechanical ventilation improved with CP"/>
 <result pre="%) patients who needed mechanical ventilation died. In early stage" exact="Covid-19" post="patients who do not need mechanical ventilation, CP treatment"/>
 <result pre="References References 1ChenN.Epidemiological and clinical characteristics of 99 cases of" exact="2019 novel coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet39510223202050751332007143 2WHOWHO coronavirus disease"/>
 <result pre="for COVID-19Lancet Infect Dis204202039840032113510 5Van GriensvenJ.Evaluation of convalescent plasma for" exact="Ebola" post="virus disease in GuineaN Engl J Med37412016334226735992 6KoJ.-H.Challenges of"/>
</results>
